Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes

Gustav Holmgren, Anna-Karin Sjögren, Isabel Barragan, Alan Sabirsh, Peter Sartipy, Jane Synnergren, Petter Björquist, Magnus Ingelman-Sundberg, Tommy B. Andersson and Josefina Edsbagge
Drug Metabolism and Disposition September 2014, 42 (9) 1401-1406; DOI: https://doi.org/10.1124/dmd.114.059154
Gustav Holmgren
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Karin Sjögren
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Barragan
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Sabirsh
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Sartipy
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Synnergren
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petter Björquist
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Ingelman-Sundberg
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tommy B. Andersson
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefina Edsbagge
Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Human pluripotent stem cells (hPSC) have the potential to become important tools for the establishment of new models for in vitro drug testing of, for example, toxicity and pharmacological effects. Late-stage attrition in the pharmaceutical industry is to a large extent caused by selection of drug candidates using nonpredictive preclinical models that are not clinically relevant. The current hepatic in vivo and in vitro models show clear limitations, especially for studies of chronic hepatotoxicity. For these reasons, we evaluated the potential of using hPSC-derived hepatocytes for long-term exposure to toxic drugs. The differentiated hepatocytes were incubated with hepatotoxic compounds for up to 14 days, using a repeated-dose approach. The hPSC-derived hepatocytes became more sensitive to the toxic compounds after extended exposures and, in addition to conventional cytotoxicity, evidence of phospholipidosis and steatosis was also observed in the cells. This is, to the best of our knowledge, the first report of a long-term toxicity study using hPSC-derived hepatocytes, and the observations support further development and validation of hPSC-based toxicity models for evaluating novel drugs, chemicals, and cosmetics.

Footnotes

    • Received May 20, 2014.
    • Accepted June 30, 2014.
  • This work was supported by SCR&Tox, which is funded by the European Commission within its seventh framework Programme and Cosmetics Europe; European Cosmetics Association, as part of the SEURAT (toward the replacement of in vivo repeated dose system toxicity) Cluster [Contract HEALTH-F5–2010-266573]; and Systems Biology Research Centre (University of Skövde) under grants from the Knowledge Foundation [2011/0295].

  • dx.doi.org/10.1124/dmd.114.059154.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 42 (9)
Drug Metabolism and Disposition
Vol. 42, Issue 9
1 Sep 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Long-Term Toxicity Testing Using hPSC-Derived Hepatocytes

Gustav Holmgren, Anna-Karin Sjögren, Isabel Barragan, Alan Sabirsh, Peter Sartipy, Jane Synnergren, Petter Björquist, Magnus Ingelman-Sundberg, Tommy B. Andersson and Josefina Edsbagge
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1401-1406; DOI: https://doi.org/10.1124/dmd.114.059154

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Long-Term Toxicity Testing Using hPSC-Derived Hepatocytes

Gustav Holmgren, Anna-Karin Sjögren, Isabel Barragan, Alan Sabirsh, Peter Sartipy, Jane Synnergren, Petter Björquist, Magnus Ingelman-Sundberg, Tommy B. Andersson and Josefina Edsbagge
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1401-1406; DOI: https://doi.org/10.1124/dmd.114.059154
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communications

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics